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Abstract 
Background: Because of the growing prevalence of terminal heart failure on the one hand 
and organ shortage on the other hand, an optimal care of heart transplant recipients based on 
the knowledge of potential risk factors not only early, but also in a long-term course after 
heart transplantation is of great importance. Therefore, the aim of the present study was to 
identify predisposing factors for late mortality in this patient collective. 
Methods: Data from long-term heart transplant patients collected during follow-up visits in 
the current center were retrospectively analyzed. Clinical, laboratory, including immune 
monitoring and apparative examination results were studied with regard to all-cause mortality.    
Results: 172 patients after heart transplantation (mean: 13.2 ± 6.4 years) were divided into 
two groups: survivors (n = 133) and non-survivors (n = 39). In comparison with survivors, 
non-survivors were characterized by significantly more pronounced renal insufficiency with 
more frequent dialysis, anemia and worse functional status. Additionally, non-survivors 
obtained hearts from relevantly more obese donors. In a multivariate Cox regression analysis 
the following parameters were shown to be independent risk factors for increased mortality: 
CD4 percentage < 42%, C-reactive protein ≥ 0.5 mg/dL, presence of rejections requiring 
therapies in the past, onset of cardiac allograft vasculopathy < 5 years following heart 
transplantation with no use of beta-blockers.  
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Conclusions: Low CD4+ cell percentages, sustained inflammation, relevant organ rejections, 
early onset of transplant vasculopathy and no use of beta-blockers are risk factors for higher 
mortality in a long-term follow-up after heart transplantation.   
Key words: heart transplantation, immune monitoring, inflammation, organ rejection, 
transplant vasculopathy, beta-blocker therapy 
 
 
INTRODUCTION  
Heart failure is an increasing health disorder worldwide [1]. As ultima ratio therapy, 
heart transplantation (HTx) has been proven to be an effective method of treatment in selected 
groups of patients with terminal heart failure refractory to other treatments [2]. However, a 
declining number of heart donors is a growing problem [3] which demands optimized 
management of the pre-, peri- and post transplantation stages in order to effectively prolong 
organ function and reduce mortality. In contrast to numerous investigations on risk factors, 
potential complications and therapy options in the early phase following HTx [4, 5], there are 
relevantly few studies examining factors influencing survival many years after HTx [6–8]. 
Furthermore, the results of these studies cannot be extrapolated to long-term survival as 
various factors and/or to a different extent may be associated with short- and long-term 
survival [6, 7, 9, 10]. Some determinants such as malignancy, infection [6, 7, 11], chronic 
rejection [7, 11], chronic allograft vasculopathy [11], idiopathic dilated cardiomyopathy and 
younger recipient age [8] were associated with late mortality following HTx. However, 
factors predicting mortality in long-term heart transplant survivors are still unknown in many 
cases.  
Therefore, the aim of the present study was to define determinants favoring prolonged 
survival in heart transplant patients. Beyond clinical, standard laboratory and apparative 
findings, the focus was placed on results from immune monitoring which reflects present 
immune/inflammatory status of patients.  
 
METHODS 
Data collection 
The current retrospectively analyzed data were collected during the last control visits 
of heart transplant patients in the out-patient Department of Cardiology I at the University of 
Muenster. Of 483 patients who underwent HTx in the Department of Cardiothoracic Surgery 
at the University of Muenster between 1990 and 2018, 311 were excluded from the present 
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study because of loss to follow-up (n = 309) or HTx less than 3 years till follow-up (n = 2) 
(Fig. 1). During follow-up visits routine examinations including patient history, current 
complaints and medication, physical examination, assessment of functional capacity, arterial 
pressure, electrocardiogram, echocardiography and laboratory blood tests were conducted.  
Standard laboratory blood tests consisted of measurements of electrolyte 
concentrations, renal and hepatic function, blood count, clotting parameters, inflammatory 
factors, NT-pro-B-type natriuretic peptide (NT-proBNP) and levels of immunosuppressive 
drugs such as cyclosporine A (CsA), everolimus, tacrolimus, mycophenolate mofetil (MMF) 
and prednisolone depending on the current immunosuppressive medication. Additionally, 
immune monitoring encompassing total lymphocyte number, numbers and percentages of 
CD4+, CD8+, CD19+ and natural killer cells was performed. Further, in order to exclude 
current relevant viral or fungal infections respective molecular and serological examinations 
were conducted. 
Inclusion criteria were HTx at least 3 years till follow-up and age > 18 years at follow-
up. Additionally, only patients in whom all the above mentioned parameters were determined 
within one visit at latest one year before the current assessment of the alive status or the date 
of death were enrolled in the study. All instable patients defined as patients presenting a status 
demanding relevant changes in their current medication and/or hospitalization were excluded 
from the study. Heart retransplantation was an additional exclusion criterion.     
The study was performed according to the Declaration of Helsinki and the study 
protocol was approved by the local Ethics Committee of the University of Muenster.   
 
Statistical analysis 
Statistical analysis was conducted with IBM SPSS Statistics, version 25. Parametric 
values were expressed as means  standard deviation (SD). Differences between the means of 
the two groups were assessed by the Student t-test. Comparisons between categorical 
variables were performed using the χ2 test. Two-tailed bivariate correlations were determined 
by the Pearson coefficient.  
Potential risk factors for death were examined by the use of univariable and 
multivariable Cox proportional hazard function analyses. Variables showing a p < 0.05 in the 
univariate Cox analysis were introduced in a multivariable Cox model and a stepwise 
selection process was used to select the final independent predictors of mortality. Survival in 
groups depending on the risk factors identified in the multivariable Cox analysis was 
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compared with the log-rank test and was illustrated using the Kaplan-Meier curves. P < 0.05 
was defined as statistically significant.  
 
RESULTS 
Patient characteristics 
172 patients at least 3 years after HTx (mean: 13.2  6.4 years) were divided into two 
groups according to survival (survivors, n = 133; non-survivors, n = 39). There were no 
significant differences in demographics, including age, sex and body mass index (BMI), the 
presence of cardiovascular risk factors and extent of vasculopathy in coronary, carotid and 
peripheral arteries and left ventricular ejection fraction (LVEF) between the groups at follow-
up. Parameters connected to HTx such as age at the time of HTx, time on the HTx list, 
urgency of the procedure and the frequency of the ventricular assist device (VAD) use prior 
HTx did not relevantly differ between both groups. Non-survivors were characterized by 
significantly worse functional status according to the New York Heart Association (NYHA) 
Classification, earlier onset of transplant vasculopathy, more reduced right ventricular systolic 
function expressed as tricuspid annular plane systolic excursion (TAPSE), less frequent use of 
beta-blockers (BB) and more frequent use of platelet aggregation inhibitors and they were 
significantly more often on dialysis. Moreover, patients from the non-survivor group 
presented a tendency toward a higher average heart frequency and more frequent development 
of precarcinoma/carcinoma. The analysis of donor-associated factors demonstrated relevantly 
higher body weight in the non-survivor group. Most patients from both groups prior HTx 
suffered from heart failure as a result of dilated cardiomyopathy, followed by ischemic heart 
disease and congenital cardiomyopathy. In the group of non-survivors, the majority of 
patients died of malignancy and infections. The most frequent causes of death of donors 
comprised of traumatic brain injury as well as subarachnoidal and intracerebral hemorrhage, 
without any relevant differences between the groups (Table 1).   
Of note, when comparing patients with early onset of transplant vasculopathy to those 
with late onset, independently of survival status, patients with early onset of transplant 
vasculopathy were significantly older prior HTx (55.3  8.3 vs. 44.6  15.1 years, p = 0.016, 
respectively) and donors presented with tendentially higher weight (82.3  13.3 vs. 72.4  
17.3 kg, p = 0.068, respectively). Additionally, a comparison between patients with and 
without transplant vasculopathy irrespective of the time of onset and survival status 
demonstrated some significant differences in clinical and laboratory parameters presented in 
the Table 2. 
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Immunosuppression and rejection 
The most frequent immunosuppressive therapy in both patient groups was a CsA-
based one, followed by everolimus and tacrolimus therapies (Fig. 2A). The overwhelming 
number of survivors and non-survivors were on an additional therapy with low-dose 
prednisolone (n = 104, 78.2% vs. n = 34, 87.2%, p = 0.215) without differences in daily doses 
(3.7  2.4 mg vs. 4.3  2.2 mg, p = 0.198) between both groups.  
The analysis of distinct subgroups of patients according to three main 
immunosuppressants: CsA, everolimus and tacrolimus, each combined with MMF showed in 
contrast to everolimus and tacrolimus significantly higher blood concentrations of CsA in the 
non-survivor versus survivor group (Fig. 2B–D).  
MMF blood levels were similar both in survivors and non-survivors in the above 
mentioned three subgroups (Fig. 2B–D) and when comparing all survivors and non-survivors 
taking MMF, independently of the immunosuppressive co-medication (2.2  1.8 ng/mL vs. 
2.2  1.6 ng/mL, p = 0.962, respectively).    
Cellular-mediated rejections were classified into three grades according to the 
International Society of Heart and Lung Transplantation (ISHLT) grading system [12]. 
Total rejection number from HTx till the last follow-up was similar in both groups. 
There was a tendency in the frequency of therapy requiring rejections toward the non-survivor 
group. Of note, the vast majority of therapy requiring rejections occurred within two years 
after HTx in both groups (Table 3).  
 
Immunological status and inflammation 
Immunological monitoring revealed significantly lower percentage of CD4+ cells 
among all lymphocytes in the blood in non-survivors versus survivors. Conversely, CD8+ cell 
portion was relevantly higher in this patient group. As a consequence, the CD4/CD8 ratio 
tended to be lower in non-survivors. In contrast, there were no significant differences in the 
levels of other lymphocyte populations, such as CD19+ cells and natural killer cells between 
the groups. 
Inflammatory response expressed as elevated leukocyte numbers, C-reactive protein 
(CRP) and interleukin (IL)-6 levels was significantly more pronounced in non-survivors 
(Table 3).  
 
Chronic kidney disease, heart failure and anemia 
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Non-survivors were characterized by worse renal function expressed as a lower 
glomerular filtration rate (GFR) and higher urea concentrations in the blood. Moreover, the 
diagnosis of anemia, defined according to the World Health Organization classification as 
haemoglobin (Hb) < 13 g/dL for men and Hb < 12 g/dL for women [13], was significantly 
more frequent in non-survivors. The morphological and biochemical analysis of erythrocytes 
showed macrocytic and hypochromic anemia.  
NT-pro-B-type natriuretic peptide (NT-proBNP) values were significantly higher in 
non-survivors, although echocardiographically estimated LVEF did not differ between the 
groups (Table 4).  
 
Univariate and multivariate Cox analyses  
In the multivariate Cox analysis only five determinants among other potential risk 
factors tested in the univariate Cox analysis such as NYHA stages II and III vs. I (p = 0.033) 
and dialysis (p = 0.108) showed a clear, statistically significant negative influence on the 
survival of heart transplant patients. These were: percentage of CD4+ cells < 42% (hazard 
ratio [HR]: 1.984, confidence interval [CI]: 1.020–3.859, p = 0.044), CRP  0.5 mg/dL (HR: 
3.422, CI: 1.767–6.626, p < 0.001), rejections requiring therapies (HR: 2.236, CI: 1.157–
4.319, p = 0.017), early onset of transplant vasculopathy < 5 years following HTx (HR: 2.741, 
CI: 1.145–6.558, p = 0.024) and no use of BB (HR: 2.358, CI: 1.194–4.656, p = 0.013; Fig. 3).     
 
Correlations 
The above mentioned five factors influencing survival in the multivariate analysis 
were correlated with other measures. Significant correlations are depicted in Table 5.  
 
DISCUSSION 
The present study has shown that the main factors influencing survival in long-term 
follow-up after HTx were connected to immunomodulation/inflammation, severe organ 
rejections, early onset of transplant vasculopathy and drug therapy.  
Specifically, higher percentages of CD4+ cells were associated with significantly 
longer survival. CD4+ cells are central cells in the rejection process [14]. In the early stage 
after HTx these cells may mediate rejection responses against donor tissue causing 
cardiovascular damage with subsequent organ failure. Therefore, the consequent 
immunosuppressive therapy is mandatory to preserve normal structure and function of the 
transplanted heart. In contrast, aggressive immunosuppression in a long-term course is not 
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needed because of a slowly developing immune tolerance. The present findings indicate that 
lower percentages of CD4+ cells may be associated with enhanced mortality many years after 
HTx. It may be related to two main reasons. On the one hand, reduced CD4 levels result 
mostly from higher blood concentrations of immunosuppressive drugs [15]. In the current 
study, subgroup analysis according to the immunosuppressive medication demonstrated that 
non-survivors treated with CsA-based immunosuppressive therapy had relevantly higher CsA 
blood concentrations compared to the corresponding survivor subgroup. As CsA therapy is 
connected to many side-effects, e.g. renal insufficiency [16] which indeed was more 
pronounced in the non-survivor group, relatively low CD4+ cell percentages could be seen as 
an indicator of an overly intensive drug therapy. However, in the subgroup of patients with 
tacrolimus-based immunosuppressive treatment, there were no significant differences in 
tacrolimus blood concentrations in spite of significantly higher CD4+ cell levels in survivors. 
In the subgroup with everolimus as a main immunosuppressant there were no relevant 
differences in everolimus or CD4 concentrations between survivors and non-survivors. No 
significant correlations were found between the percentage of CD4+ cells and the levels of the 
immunosuppressive medication used. Moreover, although, it is known that low blood levels 
of CD4+ cells may lead to the renal failure [17] and vice versa reduced CD4+ cell percentage 
may be the result of an impaired renal function [18], no relevant correlations were 
demonstrated for CD4% and renal function. This emphasizes the high complexity of an 
immune answer indicating individual response of organism to immunosuppressive therapy, 
renal function and/or additional mechanisms influencing CD4+ cell levels in the blood. This 
result shows that monitoring of drug concentrations and/or of renal function in the blood may 
be not sufficient to assess current immunological status and thus its impact on the body [19]. 
The other explanation of low CD4+ cell-associated mortality in the current collective of 
patients could be the creation of a prolonged subclinical immunosuppressive state with 
susceptibility to developing sustained inflammation, infections and tumour diseases. Indeed, 
increased leukocyte numbers were found to be significant, as well as CRP and IL-6 levels in 
non-survivors. Additionally, CRP correlated negatively with CD4+ cell percentages. 
Furthermore, CRP was another factor that predicted higher mortality in a multivariate analysis. 
Chronic inflammation, indicated by increased CRP levels is a known independent factor for 
cardiovascular and all-cause mortality [20]. Prolonged immunosuppressive state may have 
also influenced a tendency toward increased prevalence of precarcinoma/tumor diseases [21]. 
This could have also emerged from the side-effects of immunosuppressive drugs [21]. In the 
present study patients were free of infections based on anamnesis, physical examination, 
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laboratory and microbiological tests at follow-up. However, occult infections, not routinely 
tested in the current laboratory, could not be excluded. The results from the mortality data 
support the above hypothesis as the main causes of death in our patient population were 
malignant tumors and infections. 
Furthermore, it has been shown that CD4 cell lymphopenia may accelerate the 
development of cardiovascular atherosclerotic complications in renal transplant recipients 
[22] which augments mortality risk. In the current study there were no significant differences 
in the occurrence and severity of transplant vasculopathy between survivors and non-
survivors despite relevantly different levels of CD4+ cells. However, data concerning CD4+ 
cell blood concentrations in the past as atherosclerotic lesions were detected and invasively 
treated are missing, so that this issue cannot be covered by the present study.  
The next parameter which was shown to be relevant in the context of survival was the 
presence of rejections requiring therapies in the past. In contrast, weaker rejections without 
the need for drug therapy were not of relevance regarding mortality. As gross of rejections 
requiring therapies occurred early after HTx, points to a dual role of CD4+ cells in the 
outcome depending on the time course after HTx. Whereas an intense suppression of 
immunological response involving activation of CD4+ cells prevents rejections and thus 
organ failure early after HTx, the continuation of a strong elimination of CD4+ cells years 
following HTx may contribute to higher mortality. Therefore, continuous adjustments of 
immunosuppressive therapy strategies as well as close monitoring of immunological status in 
the blood are important actions at every time stage after HTx.  
Immunological status, together with the side-effects of drug therapy, cardiovascular 
risk factors and donor and recipient demographics at the time point of HTx procedure 
influence the onset of transplant vasculopathy [23]. Interestingly, the present study showed 
that there were no significant differences in the prevalence of transplant vasculopathy 
between survivors and non-survivors at the time point of the last follow-up. The presence of 
transplants vasculopathy was also not a factor influencing mortality in the Cox analysis. 
Patients with transplant vasculopathy were characterized by elevated cardiovascular risk 
factors such as diabetes mellitus, renal insufficiency, they were more obese, had longer heart 
transplant from older and more obese donors and differed from non-transplant vasculopathy 
patients in cardiovascular medication. Since survivors presented significantly less frequent 
transplant vasculopathy less than five years after HTx compared with non-survivors in this 
study, this finding suggests that, not just the presence of transplant vasculopathy is critical for 
survival, but much more the time point of its development. It is known that the immune 
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mechanisms and the influence of immunomodulating drug therapy prevail in the development 
of transplant vasculopathy at early stages, whereas classical cardiovascular risk factors may 
play a greater role later in the time course [23]. In the present patient population typical 
cardiovascular risk factors at follow-up were equally distributed across both groups. Patients 
with early onset of transplant vasculopathy were significantly older at the HTx and the hearts 
were derived from tendentially more obese donors. This suggests that the early occurrence of 
transplant vasculopathy and thus higher risk of longer duration of transplant vasculopathy and 
the pathomechanisms determining its onset, including donor- and recipient-associated factors 
may influence long-term outcome following HTx.  
The last factor presented to influence survival of long-term heart transplant patients 
was the therapy with BB in this study. Survivors obtained significantly more frequent BB 
treatment than non-survivors. As a consequence, the average heart frequency tended to be 
lower in these patients. Beta-blocker is a known drug reducing mortality in patients with 
systolic heart failure and in selected populations of patients with myocardial infarction 
without systolic heart failure [1, 24]. Its beneficial effects on cardiovascular system 
encompass blockade of beta-adrenoreceptor, reduction in sympathetic activity, antioxidant 
and anti-arrhythmic properties, positive actions on myocardial metabolism and protection of 
endothelium [25]. Patients did not show systolic heart failure with on average preserved 
LVEF in both groups. Some patients were on diltiazem instead of BB therapy. In contrast to 
BB which application has been associated with better long-term outcomes after HTx, the use 
of diltiazem did not show any advantage with regard to survival despite a similar reduction of 
heart frequencies as under BB [26]. Although it is known that diltiazem enhances CsA and 
tacrolimus concentrations in the blood and thus reduces the need of higher CsA and 
tacrolimus doses [27] and has positive effects on transplant vasculopathy [23] and 
cardiopulmonary performance [28], giving preference to BB therapy in a selected group of 
patients could be advantageous considering results from this study.     
 
Limitations of the study 
The present study has some limitations. The most important one is connected to its 
retrospective character and thus descriptive results. Additionally, the number of patients 
enrolled was relatively low. On the other hand, this statement relativizes itself when taking 
into consideration the monocentric design of the study. Furthermore, no differentiation into 
CD4 subtypes such as regulatory and effector T cells [29] was performed. However, the aim 
of this work was to search for simple predictors of mortality which can be determined easily 
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and inexpensively in routine diagnostics. Finally, the findings from immune monitoring were 
completely available only at the last follow-up visit, so we cannot answer the question about 
the blood levels of immune cells as transplant vasculopathy was initially diagnosed or as 
respective organ rejections were detected and treated.  
 
CONCLUSIONS 
Taken together, the present study showed that lower CD4+ blood levels, systemic 
inflammation, organ rejections requiring therapies, early diagnosis of transplant vasculopathy 
and no use of BB therapy were associated with increased mortality in a long-term time course 
after HTx.  
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Figure 1. Flowchart of the study.  
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Figure 2. A–D. Immunosuppressive therapy in survivors and non-survivors; CsA — 
cyclosporine A; MMF — mycophenolate mofetil; FK506 — tacrolimus; *p < 0.05 
(significant). 
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Figure 3 Kaplan-Meier curves show differences in survival of patients after heart 
transplantation (HTx). Factors positively influencing survival in patients after heart 
transplantation; A. CD4 percentage equal or above 42%; B. C-reactive protein (CRP) blood 
concentrations under 0.5 mg/dL; C. No rejections requiring therapy; D. Late onset of 
transplant vasculopathy (TV) 5 years or more following heart transplantation; E. The use of 
beta-blockers; *p < 0.05 (significant). 
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Table 1. Clinical characteristics of patients at follow-up. 
Parameters Survivors 
(group 1) 
N = 133 
Non-survivors 
(group 2) 
N = 39 
P 
Age [years] 59.2 ± 15.4 58.5 ± 16.7 0.821 
Male sex 96 (72.2%) 32 (82.1%) 0.214 
Body mass index [kg/m²] 26.2 ± 5.4 25.1 ± 5.6 0.265 
Age at HTx [years] 44.7 ± 15.0 47.6 ± 14.9 0.273 
Time on HTx transplant list [months] 288.3 ± 326.1 286.7 ± 350.3 0.980 
High urgency 51 (38.3%) 14 (35.9%) 0.782 
VAD prior HTx 47 (35.3%) 12 (30.8%) 0.597 
Follow-up after HTx [years] 14.0 (6.5%) 10.4 (5.2%) 0.002* 
Clinical examination    
NYHA > 1 55 (41.4%) 26 (66.7%) 0.005* 
Systolic BP [mmHg] 126 ± 20 121 ± 15 0.158 
Diastolic BP [mmHg] 79 ± 11 76 ± 9 0.088 
Heart frequency 82 ± 13 86 ± 13 0.099 
Echocardiography    
LVEF [%] 55.7 ± 7.3 55.9 ± 11.5 0.917 
TAPSE [mm] 16.6 ± 4.2 14.8 ± 4.4 0.019* 
Cardiovascular risk factors    
Arterial hypertension 107 (80.5%) 31 (79.5%) 0.894 
Diabetes mellitus 33 (24.8%) 13 (33.3%) 0.290 
Hypercholesterolemia 117 (88.0%) 35 (89.7%) 0.761 
Nicotine abuse   0.532 
— never smoker 117 (88.0%) 32 (82.1%)  
— current smoker 5 (3.8%) 3 (7.7%)  
— former smoker 11 (8.3%) 4 (10.3%)  
Transplant vasculopathy 53 (39.8%) 14 (35.9%) 0.656 
Transplant vasculopathy requiring invasive therapy 27 (20.3) 11 (28.2) 0.295 
Onset of transplant vasculopathy < 5 years after 
HTx 
5 (3.8%) 7 (17.9%) 0.002* 
CAD/PAD 18 (13.5%) 8 (20.5%) 0.285 
Dialysis 19 (14.3%) 12 (30.8%) 0.019* 
Precarcinoma/carcinoma 35 (26.3%) 15 (38.5%) 0.142 
Obstructive or restrictive lung diseases 21 (15.8%) 11 (28.2%) 0.080 
Cardiovascular medication    
Beta-blocker 78 (58.6%) 15 (38.5%) 0.026* 
Calcium channel inhibitor   0.754 
— Diltiazem 44 (33.1%) 11 (28.2%)  
— Dihydropyridine 33 (24.8%) 9 (23.1%)  
Ivabradine 6 (4.5%) 2 (5.1%) 0.872 
ACE inhibitor/AT1R antagonist 83 (62.4%) 18 (46.2%) 0.070 
Statin 109 (82.0%) 31 (79.5%) 0.728 
— Pravastatin equivalent dose 43.2 ± 47.9 37.4 ± 40.6 0.493 
Diuretics   0.258 
— Thiazide 2 (1.5%) 1 (2.6%)  
— Loop diuretics 69 (51.9%) 16 (41.0%)  
— Aldosterone antagonists 2 (1.5%) 1 (2.6%)  
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— Combined diuretics 11 (8.3%) 8 (20.5%)  
Platelet aggregation inhibitors   0.048* 
— ASS 33 (24.8%) 12 (30.8%)  
— Clopidogrel 24 (18.0%) 2 (5.1%)  
— Combined ASS and clopidogrel 7 (5.3%) 6 (15.4%)  
Oral anticoagulation 19 (14.3%) 7 (17.9%) 0.320 
Etiology of heart failure prior HTx   0.312 
Dilated cardiomyopathy 63 (47.4%) 14 (35.9%)  
Ischemic cardiomyopathy 46 (34.6%) 19 (48.7%)  
Congenital cardiomyopathy 10 (7.5%) 2 (5.1%)  
Arrhythmogenic right ventricular dysplasia 3 (2.3%) 0 (0.0%)  
Postpartum cardiomyopathy 1 (0.8%) 0 (0.0%)  
Non-compaction cardiomyopathy 2 (1.5%) 0 (0.0%)  
Hypertrophic cardiomyopathy 3 (2.3%) 1 (2.6%)  
Myocarditis-related cardiomyopathy  2 (1.5%) 2 (5.1%)  
Valvular cardiomyopathy 3 (2.3%) 0 (0.0%)  
Toxic cardiomyopathy 0 (0.0%) 1 (2.6%)  
Causes of death    
Malignant tumour  8 (20.5%)  
Sepsis  6 (15.4%)  
Pneumonia  4 (10.3%)  
Sudden cardiac death  4 (10.3%)  
Cardiogenic shock  3 (7.7%)  
Renal failure  2 (5.1%)  
Chronic transplant vasculopathy  2 (5.1%)  
Vascular dementia  1 (2.6%)  
Ascending aortic aneurysm  1 (2.6%)  
Hemorrhagic esophagitis  1 (2.6%)  
Unknown  7 (17.9%)  
Donor parameters    
Age [years] 31.0 ± 13.4 31.1 ± 13.9 0.949 
Body weight 71.6 ± 17.0 78.2 ± 17.2 0.048* 
Body height, mean±SD 172.8 ± 16.8 174.5 ± 22.8 0.615 
Sex (male) 71 (53.4%) 22 (56.4%) 0.859 
Causes of death:   0.148 
— Traumatic brain injury 47 (35.3%) 11 (28.2%)  
— Subarachnoidal hemorrhage 28 (21.1%) 4 (10.3%)  
—  Intracerebral hemorrhage 16 (12.0%) 7 (17.9%)  
—  Meningitis 4 (3.0%) 0 (0.0%)  
—  Cerebral ischemia 3 (2.3%) 5 (12.8%)  
—  Intracranial aneurysm 2 (1.5%) 1 (2.6%)  
—  Cerebral edema 2 (1.5%) 0 (0.0%)  
—  Hypoxic brain injury 2 (1.5%) 1 (2.6%)  
—  Polytrauma 2 (1.5%) 2 (5.1%)  
—  Gun shot skull injury 2 (1.5%) 2 (5.1%)  
—  Cardiovascular arrest 1 (0.8%) 0 (0.0%)  
—  Status epilepticus 1 (0.8%) 0 (0.0%)  
—  Strangulation 1 (0.8%) 1 (2.6%)  
—  Subdural hematoma 1 (0.8%) 0 (0.0%)  
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—  Intoxication 1 (0.8%) 0 (0.0%)  
—  Fetal death 0 (0.0%) 1 (2.6%)  
— Unknown 20 (15.0%) 4 (10.3%)  
Donor recipient sex match/mismatch   0.470 
No data 23 (17.3%) 5 (12.8%)  
Match 84 (63.2%) 25 (64.1%)  
Male  female 17 (12.8%) 8 (20.5%)  
Female  male 9 (6.8%) 1 (2.6%)  
Data are presented as a mean ± standard deviation or number (percentage); *p < 0.05 (significant); ACE — 
angiotensin-converting-enzyme; AT1R — angiotensin II type 1 receptor; BP — blood pressure; CAD — 
cerebral artery disease; HTx — heart transplantation; LVEF — left ventricular ejection fraction; NYHA — New 
York Heart Association; PAD — peripheral artery disease; TAPSE — tricuspid annular plane systolic excursion; 
VAD — ventricular assist device  
 
 
Table 2. Differences in clinical and laboratory parameters between patients with and without 
transplant vasculopathy at follow-up. 
Parameters Transplant 
vasculopathy 
(n = 105) 
No transplant 
vasculopathy 
(n = 67) 
P 
Recipient BMI [kg/m²] 27.1  5.9 25.3  5.0 0.032* 
Donor weight [kg] 77.0  15.3 70.8  18.0 0.032* 
Donor age [years] 35.4 12.3 28.2  13.5 0.001* 
Urea [mg/dL] 37.1  21.0 30.5  17.4 0.028* 
Follow-up after HTx [years] 15.6  5.7 11.7  6.3 < 0.001* 
Diabetes mellitus 24 (35.8%) 22 (21.0%) 0.032* 
Osteoporosis 11 (16.4%) 5 (4.8%) 0.010* 
Platelet aggregation inhibitors 46 (68.7%) 38 (36.2%) < 0.001* 
Oral anticoagulation 15 (22.4%) 11 (10.5%) 0.032* 
Diuretics 49 (73.1%) 61 (58.1%) 0.045* 
Data are presented as a mean ± standard deviation (SD) or number (percentage); *p < 0.05 (significant); BMI — 
body mass index; HTx — heart transplantation 
 
 
 
Table 3. Number and severity of rejections since heart transplantation till the last follow-up as 
well as immunological and inflammatory factors at follow-up in survivors and non-survivors. 
 Survivors 
(group 1) 
N = 133 
Non-survivors 
(group 2) 
N = 39 
P  
Rejections 73 (54.9%) 24 (61.5%) 0.461 
Rejection stage:   0.299 
1 31 (23.3%) 7 (17.9%)  
2 39 (29.3%) 14 (35.9%)  
3 3 (2.3%) 3 (7.7%)  
Rejections requiring therapy 45 (33.8%) 18 (46.2%) 0.160 
Rejections requiring therapy under 40 (88.9%) 13 (72.2%) 0.102 
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24 months after heart transplantation 
Leukocytes (G/l) 7.3  2.5 8.2  2.7 0.048* 
Lymphocytes [cells/µL] 1542.6 ± 687.3 1519.1 ± 960.0 0.865 
CD3 [cells/µL] 1217.7 ± 634.6 1212.8 ± 894.2 0.969 
CD3 [%] 77.3 ± 11.3 78.0 ± 11.3 0.731 
CD4 [cells/µL] 700.1 ± 325.2 616.4 ± 400.0 0.183 
CD4 [%] 46.2 ± 10.9 42.0 ± 11.8 0.042* 
CD8 [cells/µL] 480.7 ± 427.7 569.4 ± 545.4 0.287 
CD8 [%] 28.7 ± 13.5 34.2 ± 16.3 0.035* 
CD4/CD8 2.3 ± 2.0 1.7 ± 1.2 0.087 
CD19 [cells/µL] 89.7 ± 79.6 73.1 ± 86.3 0.262 
CD19 [%] 6.0 ± 5.0 4.5 ± 3.5 0.080 
Natural killers [cells/µL] 224.9 ± 151.1 214.1 ± 156.4 0.696 
Natural killers [%] 16.0 ± 10.2 15.8 ± 10.3 0.939 
Interleukin-6 [pg/mL] 9.59.8 14.220.3 0.047* 
C-reactive protein [mg/dL] 0.80.9 1.72.6 0.001* 
All percentages are expressed as the number of distinct lymphocyte subsets divided by the number of all 
lymphocytes multiplied by 100%. Data are presented as a mean ± standard deviation or number (percentage); *p 
< 0.05 (significant) 
 
 
 
 
Table 4. Laboratory parameters connected to the heart and renal function as well as red blood 
cell parameters in survivors and non-survivors. 
 Survivors 
(group 1) 
N = 133 
Non-survivors 
(group 2) 
N = 39 
P 
NT-proBNP [pg/mL] 3068.0 ± 6172.2 8397.6 ± 11303.3 < 0.001* 
GFR [mL/min/1.73 m2] 46.4  24.1 34.8  22.0 0.008* 
Urea [mg/dL] 31.1  17.4 39.9  23.0 0.011* 
Erythrocytes [T/l] 4.5  0.7 4.2  0.7 0.039* 
Hemoglobin [g/dL] 12.7  1.8 12.0  1.8 0.041* 
Hematocrit [%] 39.2 ± 5.2 37.7 ± 5.3 0.116 
Mean corpuscular volume [fL] 88.1  5.7 90.1  7.5 0.077 
Mean corpuscular hemoglobin [pg] 28.6 ± 2.1 28.8 ± 2.7 0.670 
Mean corpuscular hemoglobin 
concentration [g/dL] 
32.4  1.2 31.9  1.3 0.022* 
Data are presented as a mean ± standard deviation; *p < 0.05 (significant); GFR — glomerular filtration rate; 
NT-proBNP — NT-pro-B-type natriuretic peptide 
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Table 5. Statistically significant correlations between factors influencing survival in the 
multivariate analysis and other measures. 
Correlations P 
CD4%  
Negative correlations  
CD8%, R = –0.635 < 0.001* 
Lymphocyte number, R = –0.173 0.023* 
Natural killer cells, R = –0.226 0.003* 
C-reactive protein, R = –0.153 0.045* 
CRP  
Negative correlations  
CD4%, R = –0.153 0.045* 
CD19, R = –0.154 0.044* 
Erythrocytes, R = –0.276 < 0.001* 
Hemoglobin, R = –0.281  < 0.001* 
Hematocrit, R = –0.241 0.002* 
MCHC, R = –0.250 0.001* 
GFR, R = –0.277 < 0.001* 
Positive correlations:  
CD8%, R = 0.187 0.014* 
Prednisolone, R = 0.267  < 0.001* 
Dialysis, R = 0.312 < 0.001* 
CAD/PAD, R = 0.219 0.004* 
NT-proBNP, R = 0.450 < 0.001* 
Interleukin-6, R = 0.373 < 0.001* 
MCV, R = 0.176 0.021* 
Diuretics, R = 0.166 0.030* 
Rejections requiring therapy  
Positive correlations  
Rejection grade, R = 0.882 < 0.001* 
Transplant vasculopathy under 5 years after HTx 
Positive correlations:  
Age at HTx, R = 0.184 0.016* 
Beta-blocker  
Negative correlations  
Heart frequency, R = –0.274 < 0.001* 
Diastolic blood pressure, R = –0.165 0.030* 
*p < 0.05 (significant); CAD — cerebral artery disease; GFR — glomerular filtration rate; HTx — heart 
transplantation; MCV — mean corpuscular volume; MCHC — mean corpuscular hemoglobin concentration, 
NT-proBNP — NT-pro-B-type natriuretic peptide; PAD — peripheral artery disease 
